RxDoctor Payments Data

Richard Poppe, MD

Family Medicine · Central City, NENPI 1467012468

Payments from drug & device makers

$1,981in general payments, 2019–2025

Across 120 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$337
  • AstraZeneca$195
  • Neurocrine Biosciences, Inc.$169
  • Novo Nordisk$136
  • AbbVie$108
  • Boehringer Ingelheim$107
  • plus $929 from 25 others

What the payments were for

  • Food & beverage$1,981100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,981 in reported general payments places this provider in the 75th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$8,992
Medicare patients
53
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$42,295
OzempicSemaglutide36$35,797
FarxigaDapagliflozin Propanediol45$26,817
MyrbetriqMirabegron40$17,514
JardianceEmpagliflozin24$14,627
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,940
Tresiba Flextouch U-100Insulin Degludec15$7,395
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,917
XareltoRivaroxaban11$5,895
Breo ElliptaFluticasone/Vilanterol12$4,974
LokelmaSodium Zirconium Cyclosilicate12$4,731
CombiganBrimonidine Tartrate/Timolol13$2,803
Levetiracetam19$2,559
Tenofovir Disoproxil Fumarate11$2,430
Rosuvastatin Calcium110$2,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Lokelma$195$38,46568 claims
Novo NordiskOzempic$136$35,79736 claims
Astellas Pharma US IncMyrbetriq$15$17,51440 claims
Boehringer IngelheimJardiance$107$14,62724 claims
Johnson & JohnsonXarelto$45$5,89511 claims
AbbVieCombigan, Synthroid$108$3,81142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Central City

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →